Exciting insights about follicular lymphoma at 17-ICML
This article presents key insights from the conference, shedding light on exciting developments in the field. The knowledge and insights we gained left us inspired and energised.
Highlights from our satellite symposium
At the 17th International Conference on Malignant Lymphoma (17-ICML), the FLF hosted their own symposium: “What Will it Take to Cure FL?”. Read more to find out the key takeaways and highlights from the symposium.
Dr Mitchell Smith on Future Directions in FL
Dr Mitchell Smith on Future Directions in FL Dr Mitchell Smith, CMO at the FLF, shares his insights in what the future holds for follicular lymphoma research. In his article, he outlines the key questions in follicular lymphoma, and lays out which areas of research look to be most promising in leading us to better […]
ASH Annual Meeting 2022 – Research and insight summary
ASH Annual Meeting 2022 – summary and key take-outs By Dr Zoe Drymoussi During the 9-12th December 2022, the FLF team attended, in person, for the biggest events of the year in the world of haematology – the American Society of Hematology (ASH) annual meeting. More than 25,000 delegates, showcasing 3000+ abstracts, took over the […]
Looking back over the last 25 years for FL – the Rituximab era
Looking back over the last 25 years for FL – the Rituximab era By Dr Mitchell Smith, Chief Medical Officer A recent re-publication marking 25 years since the seminal 1998 Journal of Clinical Oncology paper (1) upon which Rituximab was approved for relapsed/refractory follicular or low-grade lymphoma (1997 by U.S. FDA, and 1998 by European […]
Research in focus: Bi-specific antibodies approval.
At a Glance: Bi-specific antibodies are a revolutionary form of immunotherapy recently approved for patients with relapsed or refractory Follicular Lymphoma (FL). Unlike traditional chemotherapy, these “dual-action” proteins act as a bridge: one arm attaches to the cancer cell while the other engages your own immune system (T-cells) to attack the lymphoma directly. This precision […]
Antibody response to CoV-2 vaccines
Interesting summary of the impact and effectiveness of antibody responses to SARS- CoV-2 vaccines in patients with hematologic malignancies. A project from Michael J. Garil Data Collective, and supported by the Leukemia & Lymphoma society. Read full article
Blood tests in Follicular Lymphoma
For many people living with Follicular Lymphoma, periodic blood tests become a regular feature. There are several reasons you might need blood tests when affected by Follicular Lymphoma (FL), a form of non-Hodgkin’s lymphoma. But does lymphoma show up in blood work? Generally, the answer is no, FL is rarely detected on standard or “routine” […]
What Are Clinical Trials? A Guide for Lymphoma Patients
At a Glance: Clinical trials are research studies that test new treatments for Follicular Lymphoma to ensure they are safe and more effective than current options. They are conducted in four distinct phases—from initial dosing (Phase I) to large-scale comparisons (Phase III). Participating in a trial gives patients early access to cutting-edge therapies, including “chemo-free” […]
The Follicular Lymphoma Foundation research goals – patient poll results – September 2021
The FLF places the patient at the heart of our organisation. This survey collated the unmet needs and prioritised our research goals.